H.C. Wainwright analyst Robert Burns lowered the firm’s price target on BioNTech (BNTX) to $134 from $145 and keeps a Buy rating on the shares following the Q1 report. The firm is factoring in higher operating expenses moving forward.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- Prasad appointment not necessarily bad news for biopharma, says Citi
- Strategic Importance of BioNTech’s COVID-19 Vaccine and Oncology Ambitions Drive Buy Rating
- BioNTech SE: Promising Oncology Pipeline and Strategic Trials Justify Buy Rating
- BioNTech price target lowered to $140 from $145 at Citi
- BioNTech SE Reports Q1 2025 Financial Results
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue